RE:You can Buy CXR tomorrow, butThis kind of info is so hard to get for analysts, let alone for retail investors, out of CXR's own management. My guess is they're way over their heads and don't have a clue. If they do, they're really good at not showing it in CCs. It's fascinating how people are willing to simply ''throw'' their money in this management's direction after what went on, and also what didn't go on ( them being transparent about material news ).
select1011 wrote: ...if I planned to, I would want to know, 1. What Scandinavian countries are now reforming their drug pricing and regulatory programs? 2. what is the revenue breakdown, country by country, drug by drug of CXR international's global business.? 3. how much of CXR internalantional's revenue is dependant on publicly funded formularies? 4. what role do private "pharmacy entities" play in the sales channels in each of the over 100 countries that CXR has such sales channels? 5. What does Brexit mean for CXR re: the loss of market certainty in the EU per this: https://ec.europa.eu/growth/sectors/healthcare/competitiveness/products-pricing-reimbursement_en 6. What improvements in sales reporting systems has CXR invested in its AMCo business since it purchased the company? 7. what 4 product acquisitions did CXR make through AMCo as reported in Q1 and how are they performing? If you feel that you are in the "I know capitulation when I see it camp" then look back to this Board in Oct/Nov 2015. If you haven't personally called every analyst who is covering this stock, you should, because you can and you don't have to be a client to get their time. Basic DD 101. Gosh, good luck tomorrow.